Vitamin C for Immune Health: Beyond the Cold

Vitamin C (ascorbic acid) has been the subject of more controversy, hype, and dismissal than almost any other nutrient in immune health. The reality sits between Linus Pauling's extravagant claims and the dismissive "it doesn't work" narrative: vitamin C has well-characterized, multi-pathway immune functions, and the evidence for its role in respiratory infections — when properly analyzed — is meaningful.

Why Immune Cells Concentrate Vitamin C

The first clue that vitamin C matters for immunity is its distribution in the body. Immune cells — particularly neutrophils, lymphocytes, and monocytes — accumulate vitamin C to levels 50–100 times higher than plasma concentration. This active accumulation requires energy-dependent transport, meaning cells are spending resources to maintain high internal vitamin C. Evolution doesn't maintain metabolically expensive systems without function.

In neutrophils, vitamin C serves multiple roles: it supports chemotaxis and phagocytosis, and after the oxidative burst (where neutrophils release reactive oxygen species to kill pathogens), vitamin C recycling prevents the neutrophil's own destruction by the oxidative damage it creates. Without adequate vitamin C, neutrophils become less effective and die faster after bacterial killing. In lymphocytes, vitamin C supports T-cell proliferation and differentiation in response to antigenic stimulation.

Antiviral Mechanisms

Vitamin C's antiviral activity operates through several pathways. It directly inhibits the replication of several viruses by interfering with RNA synthesis — demonstrated for influenza, poliovirus, and rhinovirus in in vitro studies. It enhances the production of interferon, the signaling protein that puts neighboring cells on antiviral alert. And by maintaining glutathione levels (vitamin C regenerates oxidized glutathione), it preserves the intracellular antioxidant environment that supports antiviral immune function.

At pharmacological levels achievable only through intravenous administration, vitamin C generates hydrogen peroxide in tumor cells and virus-infected cells with impaired antioxidant defenses — a mechanism that is being studied in ICU settings for severe infections including sepsis.

What the Cochrane Review Actually Says

The Cochrane meta-analysis on vitamin C and the common cold (most recently updated with 29 trials covering over 11,000 participants) is the most cited evidence on this question — and it is routinely misrepresented in both directions. The findings:

Vitamin C supplementation at 200mg/day or more did not significantly reduce cold incidence in the general population. This is the finding often cited to dismiss vitamin C.

However, regular supplementation reduced cold duration by 8% in adults and 14% in children — a clinically meaningful shortening. It also reduced cold severity scores significantly.

In people under acute heavy physical stress (marathon runners, skiers, soldiers in subarctic conditions), vitamin C supplementation reduced cold incidence by approximately 50%. This is a striking finding largely ignored in popular summaries.

Therapeutic dosing started at onset of illness did not significantly shorten duration in most trials — suggesting that maintained baseline levels matter more than acute loading.

Oral vs. IV Vitamin C

Oral vitamin C has a physiological absorption ceiling at approximately 200–500mg per dose — higher doses rapidly exceed absorptive capacity and are excreted in urine. This limits plasma levels achievable orally to roughly 70–100 micromol/L. Intravenous vitamin C bypasses intestinal absorption completely and can achieve plasma levels 50–100x higher.

Clinical interest in IV vitamin C focuses on severe infections, sepsis, and critical illness — contexts where standard oral supplementation cannot achieve therapeutic tissue concentrations. Several ICU trials (including the CITRIS-ALI trial in ARDS) have tested high-dose IV vitamin C with mixed but generally promising results. For most people managing ordinary respiratory infections, oral vitamin C at 1,000–2,000mg daily in divided doses represents a practical, evidence-supported approach.

Optimal Dosing Strategy

Maintenance: 200–500mg daily for general immune support and adequate tissue saturation. The recommended dietary allowance (75–90mg) is sufficient to prevent scurvy but does not maintain immune cell saturation.

Acute illness: 1,000mg every 4–6 hours (up to 4,000–6,000mg daily in divided doses) for the duration of illness. Dividing doses across the day maximizes absorption compared to a single large dose.

High-stress prevention: 500–1,000mg before prolonged exercise, intense cold exposure, or periods of elevated infection risk.

Liposomal vitamin C — vitamin C encapsulated in phospholipid vesicles — achieves higher plasma levels than standard oral vitamin C and represents a middle ground between oral and IV delivery. It is significantly more expensive but meaningful for people who want higher tissue concentrations without IV access.

FAQ

Q: Should I take vitamin C continuously or only when sick?

Both. The Cochrane data suggests maintained baseline levels (regular daily supplementation) are more effective than therapeutic dosing at onset alone. Start maintenance supplementation and increase dose during illness.

Q: Does vitamin C cause kidney stones?

High-dose vitamin C (above 2,000mg/day long-term) can increase oxalate excretion, theoretically increasing kidney stone risk in susceptible individuals. This concern primarily applies to those with a history of oxalate stones. For most people, doses up to 2,000mg/day are considered safe for long-term use.

Q: What about vitamin C from food versus supplements?

Whole food sources of vitamin C (bell peppers, kiwi, citrus, berries, broccoli) provide vitamin C alongside bioflavonoids and other compounds that may enhance absorption and activity. However, achieving therapeutic doses solely from food is impractical — supplementation is the realistic approach for immune support dosing.

Track your supplements in Optimize.